- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibiting RRM2 to enhance the anticancer activity of chemotherapy
Authors
Keywords
Ribonucleotide reductase subunit M2, Chemotherapy, Chemoresistance, Small interfering RNA, RRM2 inhibitors, Kinase inhibitors
Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 133, Issue -, Pages 110996
Publisher
Elsevier BV
Online
2020-11-21
DOI
10.1016/j.biopha.2020.110996
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug-Resistant Cells
- (2020) Gongshen Jin et al. Anti-Cancer Agents in Medicinal Chemistry
- MicroRNA-4500 Inhibits Migration, Invasion and Angiogenesis of Breast Cancer Cells via RRM2-dependent MAPK Signaling Pathway
- (2020) Shaoying Li et al. Molecular Therapy-Nucleic Acids
- Downregulation of miR-125b-5p and Its Prospective Molecular Mechanism in Lung Squamous Cell Carcinoma
- (2020) Shu-Ping Huang et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- ERK Inhibitor Enhances Everolimus Efficacy through Attenuation of dNTP Pools in Renal Cell Carcinoma
- (2019) Yun Zou et al. Molecular Therapy-Nucleic Acids
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine based chemotherapy
- (2019) Huimin Lu et al. BIOSCIENCE REPORTS
- Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis
- (2019) Wenxiu Qi et al. BIOCHEMICAL PHARMACOLOGY
- Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA‐5095 in cervical cancer
- (2019) Hui Zhao et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Identification of lncRNA NEAT1/miR‐21/RRM2 axis as a novel biomarker in breast cancer
- (2019) Dongling Quan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells
- (2019) Myoungjae Kim et al. MOLECULES
- The Non-Canonical Aspects of MicroRNAs: Many Roads to Gene Regulation
- (2019) Christiaan J. Stavast et al. Cells
- LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2
- (2019) Na Huang et al. Frontiers in Oncology
- miR-140-3p impedes the proliferation of human cervical cancer cells by targeting RRM2 to induce cell-cycle arrest and early apoptosis
- (2019) Jiajia Ma et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment
- (2018) Xiao Zhao et al. BIOMATERIALS
- A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
- (2018) Laeeq Malik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction
- (2018) Ping Chen et al. CLINICAL SCIENCE
- Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
- (2018) Shuhei Shinoda et al. Oncotarget
- Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers
- (2018) André Wendindondé Nana et al. Hormones & Cancer
- siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin
- (2018) Shuquan Zheng et al. Molecular Therapy-Nucleic Acids
- DHS (trans−4,4′-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2)
- (2018) Chi-Wei Chen et al. ONCOGENE
- Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression
- (2017) Siying Zhou et al. GENE
- Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
- (2017) Mukundan Baskar Mannargudi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
- (2017) Guanggai Xia et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
- (2017) Min Tu et al. Molecular Cancer
- Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype
- (2017) Jian Teng et al. NEURO-ONCOLOGY
- Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates
- (2017) Gonzalo Lopez et al. PLoS One
- Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the formation of pancreatic cancer stem like cells
- (2017) Jae Hee Cho et al. Oncotarget
- Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
- (2016) N. Fatkhutdinov et al. MOLECULAR CANCER RESEARCH
- Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine
- (2016) Zhijun Wang et al. MOLECULES
- Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640
- (2016) Clayton S. Lewis et al. Oncotarget
- Network-based approach to identify prognostic biomarkers for estrogen receptor–positive breast cancer treatment with tamoxifen
- (2015) Rong Liu et al. CANCER BIOLOGY & THERAPY
- Gemcitabine resistance in pancreatic ductal adenocarcinoma
- (2015) Yoav Binenbaum et al. DRUG RESISTANCE UPDATES
- Targeting Ribonucleotide Reductase M2 and NF- B Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
- (2015) K. N. Shah et al. MOLECULAR CANCER THERAPEUTICS
- Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer
- (2014) Rouzbeh Daylami et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells
- (2014) Mina Maftouh et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
- (2014) Y Aye et al. ONCOGENE
- Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression
- (2014) CONGFEI WANG et al. ONCOLOGY REPORTS
- Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance
- (2014) Nagireddy Putluri et al. NEOPLASIA
- Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA
- (2013) Jie Gao et al. BIOMATERIALS
- A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance
- (2013) B. Zhou et al. CANCER RESEARCH
- Targeting ribonucleotide reductase for cancer therapy
- (2013) Jimin Shao et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers
- (2013) Charles A. Kunos et al. GYNECOLOGIC ONCOLOGY
- Small Interfering RNA (siRNA)-Mediated Silencing of the M2 Subunit of Ribonucleotide Reductase
- (2013) Meng Zhang et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia
- (2013) Rebecca B. Klisovic et al. LEUKEMIA & LYMPHOMA
- AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 Inhibition
- (2013) Khyati N. Shah et al. MOLECULAR CANCER RESEARCH
- Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein
- (2013) Yangzom Doma Bhutia et al. PLoS One
- Identifying miRNAs, targets and functions
- (2012) B. Liu et al. BRIEFINGS IN BIOINFORMATICS
- Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair
- (2012) Vincenzo D'Angiolella et al. CELL
- A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer
- (2012) Ludmila Katherine Martin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
- (2012) Amir Mortazavi et al. INVESTIGATIONAL NEW DRUGS
- Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
- (2012) Charles Kunos et al. Journal of Translational Medicine
- Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells
- (2012) G. Pontarin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma
- (2011) R. J. Jones et al. BLOOD
- A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
- (2010) Srikala S. Sridhar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer
- (2010) C. A. Kunos et al. CLINICAL CANCER RESEARCH
- siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide
- (2010) Jonathan E. Zuckerman et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium
- (2010) Natasha B. Leighl et al. Journal of Thoracic Oncology
- Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers
- (2010) Charles A. Kunos et al. RADIATION RESEARCH
- Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase
- (2009) Lijun Zhu et al. BIOCHEMICAL PHARMACOLOGY
- Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response
- (2009) Yong-Wei Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Modulating Radiation Resistance by Inhibiting Ribonucleotide Reductase in Cancers with Virally or Mutationally Silenced p53 Protein
- (2009) Charles A. Kunos et al. RADIATION RESEARCH
- Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
- (2008) J Souglakos et al. BRITISH JOURNAL OF CANCER
- Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors
- (2008) Romano Danesi et al. PHARMACOGENOMICS
- Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
- (2008) Ioannis Boukovinas et al. PLoS One
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now